Sudhir Srivastava

List of Publications by Year
in descending order

51 papers	4,269 citations	218677 26 h-index	197818 49 g-index
51 all docs	51 docs citations	51 times ranked	6557 citing authors

#	Article	IF	Citations
1	Early Detection Initiative: A randomized controlled trial of algorithm-based screening in patients with new onset hyperglycemia and diabetes for early detection of pancreatic ductal adenocarcinoma. Contemporary Clinical Trials, 2022, 113, 106659.	1.8	20
2	Multicancer early detection test: Preclinical, translational, and clinical evidenceâ€“generation plan and provocative questions. Cancer, 2022, 128, 861-874.	4.1	7
3	Extracellular Vesicles in Cancer Detection: Hopes and Hypes. Trends in Cancer, 2021, 7, 122-133.	7.4	86
4	Synthetic biomarkers: a twenty-first century path to early cancer detection. Nature Reviews Cancer, 2021, 21, 655-668.	28.4	84
5	A high-stringency blueprint of the human proteome. Nature Communications, 2020, 11, 5301.	12.8	152
6	The National Cancer Institute Early Detection Research Network: Two Decades of Progress. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2396-2400.	2.5	4
7	Cancer Biomarkers and Big Data: A Planetary Science Approach. Cancer Cell, 2020, 38, 757-760.	16.8	13
8	The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2401-2410.	2.5	13
9	Pan-Cancer Early Detection: Hype or Hope?. Cancer Cell, 2020, 38, 23-24.	16.8	20
10	National Cancer Institute Think-Tank Meeting Report on Proteomic Cartography and Biomarkers at the Single-Cell Level: Interrogation of Premalignant Lesions. Journal of Proteome Research, 2020, 19, 1900-1912.	3.7	8
11	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. Cell, 2020, 181, 236-249.	28.9	334
12	Cancer overdiagnosis: a biological challenge and clinical dilemma. Nature Reviews Cancer, 2019, 19, 349-358.	28.4	220
13	Rationale and design of the Hepatocellular carcinoma Early Detection Strategy study: A multi-center longitudinal initiative of the National Cancer Instituteâ€™s Early Detection Research Network. Contemporary Clinical Trials, 2019, 76, 49-54.	1.8	17
14	Validation: a critical step in bringing biomarkers to clinical fruition. Annals of Epidemiology, 2018, 28, 135-138.	1.9	4
15	The PreCancer Atlas (PCA). Trends in Cancer, 2018, 4, 513-514.	7.4	22
16	The Making of a PreCancer Atlas: Promises, Challenges, and Opportunities. Trends in Cancer, 2018, 4, 523-536.	7.4	36
17	Summarizing performance for genome scale measurement of miRNA: reference samples and metrics. BMC Genomics, 2018, 19, 180.	2.8	5
18	Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA Oncology, 2017, 3, 1085.	7.1	120

#	Article	IF	Citations
19	Molecular Detection and Diagnosis of Cancer. , 2017, , 797-809.		2
20	Research Needs for Understanding the Biology of Overdiagnosis in Cancer Screening. Journal of Cellular Physiology, 2016, 231, 1870-1875.	4.1	17
21	Generating a focused view of disease ontology cancer terms for pan-cancer data integration and analysis. Database: the Journal of Biological Databases and Curation, 2015, 2015, bav032-bav032.	3.0	40
22	Leveraging Biospecimen Resources for Discovery or Validation of Markers for Early Cancer Detection. Journal of the National Cancer Institute, 2015, 107, .	6.3	20
23	Definitive Characterization of CA 19-9 in Resectable Pancreatic Cancer Using a Reference Set of Serum and Plasma Specimens. PLoS ONE, 2015, 10, e0139049.	2.5	31
24	Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncology, The, 2014, 15, e234-e242.	10.7	423
25	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. Journal of Clinical Oncology, 2014, 32, 4066-4072.	1.6	234
26	The Early Detection Research Network's Specimen Reference Sets: Paving the Way for Rapid Evaluation of Potential Biomarkers. Clinical Chemistry, 2013, 59, 68-74.	3.2	50
27	The Early Detection Research Network: 10-Year Outlook. Clinical Chemistry, 2013, 59, 60-67.	3.2	28
28	Systematic, Evidence-Based Discovery of Biomarkers at the National Cancer Institute. International Journal of Gynecological Cancer, 2012, 22, S41.	2.5	1
29	Systematic, evidence-based discovery of biomarkers at the NCI. Clinical and Experimental Metastasis, 2012, 29, 645-652.	3.3	22
30	New paradigms in translational science research inÂcancer biomarkers. Translational Research, 2012, 159, 343-353.	5.0	47
31	A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [â^'2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1193-1200.	2.5	186
32	Î±-Fetoprotein, Des-Î³ Carboxyprothrombin, and Lectin-Bound Î±-Fetoprotein in Early Hepatocellular Carcinoma. Gastroenterology, 2009, 137, 110-118.	1.3	644
33	Biomarkers in oncology research and treatment: early detection research network: a collaborative approach. Biomarkers in Medicine, 2008, 2, 181-195.	1.4	7
34	Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine, 2007, 4, 33-43.	1.5	4
35	Cancer biomarker discovery and development in gastrointestinal cancers: early detection research network-a collaborative approach. Gastrointestinal Cancer Research: GCR, 2007, 1, S60-3.	0.7	9
36	Molecular Screening of Cancer. Molecular Diagnosis and Therapy, 2006, 10, 221-230.	3.8	10

#	Article	IF	Citations
37	Keynote review: Recent advances in biomarkers for cancer diagnosis and treatment. Drug Discovery Today, 2005, 10, 965-976.	6.4	97
38	Biomarkers in molecular medicine: cancer detection and diagnosis. BioTechniques, 2005, 38, S9-S15.	1.8	91
39	Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility. Clinical Chemistry, 2005, 51, 102-112.	3.2	336
40	Proteomics in the Forefront of Cancer Biomarker Discoveryâ€. Journal of Proteome Research, 2005, 4, 1098-1103.	3.7	40
41	Proteomic Maps of the Cancer-Associated Infectious Agentsâ€. Journal of Proteome Research, 2005, 4, 1171-1180.	3.7	11
42	The Promise of Biomarkers in Colorectal Cancer Detection. Disease Markers, 2004, 20, 87-96.	1.3	11
43	Molecular diagnostics: a new frontier in cancer prevention. Expert Review of Molecular Diagnostics, 2004, 4, 503-511.	3.1	17
44	Challenges for Biomarkers in Cancer Detection. Annals of the New York Academy of Sciences, 2004, 1022, 9-16.	3.8	102
45	Proteomic analysis of cancer-cell mitochondria. Nature Reviews Cancer, 2003, 3, 789-795.	28.4	95
46	New Cancer Biomarkers Deriving from NCI Early Detection Research. Recent Results in Cancer Research, 2003, 163, 72-84.	1.8	51
47	Epigenetics in cancer: implications for early detection and prevention. Lancet Oncology, The, 2002, 3, 755-763.	10.7	148
48	Proteomics for cancer biomarker discovery. Clinical Chemistry, 2002, 48, 1160-9.	3.2	186
49	Early Detection Cancer Research Network. Laboratory Investigation, 2000, 80, 1147-1148.	3.7	48
50	Nuclear accumulation of p53 in colorectal adenocarcinoma. Cancer, 1998, 83, 2456-2467.	4.1	70
51	Early detection research program at the NCI. , 1996, 69, 35-37.		26